|
시장보고서
상품코드
1867542
세계의 겸상 적혈구 빈혈 치료제 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Sickle Cell Anemia Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
겸상 적혈구 빈혈 치료제 시장 규모는 2024년에 40억 6,700만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 13.7%로 성장하여 2031년까지 99억 8,800만 달러로 확대될 것으로 예측됩니다.
겸상적혈구증(SCD)은 베타글로빈 유전자의 돌연변이로 인해 발생하는 만성 유전성 혈액질환으로, 비정상적인 헤모글로빈인 겸상 헤모글로빈(HbS)이 생성되는 질환입니다. 저산소 상태에서는 HbS가 중합되어 적혈구가 경직된 낫 모양(낫 모양)을 취합니다. 이러한 변형된 세포는 용혈을 일으키기 쉽고, 혈관을 막아 통증, 빈혈, 장기 손상을 유발합니다. 치료 방법으로는 약물요법(예: 하이드록시우레아, L-글루타민), 유전자 치료, 조혈모세포 이식, 지지요법 등이 있습니다.
겸상적혈구증 치료제의 세계 주요 기업으로는 Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics 등이 있습니다. 시장 규모로는 아메리카 대륙이 약 55%로 가장 큰 점유율을 차지하고 있으며, 유럽, 중동 및 아프리카가 각각 35% 이상의 점유율을 차지하고 있습니다. 제품별로는 수혈이 35% 이상의 점유율로 가장 큰 비중을 차지하고 있습니다. 또한, 적응증별로는 소아가 가장 많고, 그 다음이 성인입니다. 겸상적혈구증 치료 환경은 빠르게 발전하고 있으며, 주요 제약사(예: 화이자, 노바티스, 노보노디스크)가 전문 바이오 기업(예: 블루버드 바이오, 크리스퍼 테라퓨틱스, 이마라, 엠마우스 메디컬)과 공동으로 투자하고 있습니다. 승인된 치료법은 엠마우스의 L-글루타민과 같은 저분자 약물부터 블루버드(Bluebird)의 진테그로(Zintegro)와 CRISPR/버텍스(Vertex)의 카스게비(Casgevy)와 같은 유전자 치료법을 통한 근본적인 접근법까지 다양하며, 지속적이고 잠재적으로 단회투여 가능한 치료법으로의 전환을 보여주고 있습니다. 향후 개발에서는 유전자 치료에 대한 환자 접근성 확대, 장기 안전성 확보, 줄기세포 이식을 위한 전처치 프로토콜 개선이 우선 과제가 될 것입니다. 새로운 접근법으로 항접착제(GlycoMimetics), 일산화질소 조절제(Prolong), 대식세포 표적치료제(Modus) 등 개발 파이프라인을 다각화하고 있습니다. 임상 혁신의 발전과 규제 측면의 지원적 모멘텀에 힘입어, 이 분야는 특히 의료 서비스가 부족한 전 세계 사람들을 대상으로 증상 치료에서 기능적 치료로 전환하고 있습니다.
이 보고서는 겸상적혈구증 치료제 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
겸상적혈구증 치료제 시장 규모, 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함합니다. 본 보고서는 정량적, 정성적 분석을 통해 독자들이 겸상적혈구 빈혈 치료제 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 사업적 판단을 내리는데 도움을 드립니다.
시장 세분화
기업별
- Emmaus Medical
- Theravia
- Pfizer
- Novartis
- Bluebird Bio
- Novo Nordisk
- Gamida Cell
- CRISPR Therapeutics
- GlycoMimetics
- Prolong Pharmaceuticals
- Modus Therapeutics
- Sangamo Biosciences
- Bioverativ
- Imara
- Ironwood Pharmaceuticals
유형별 부문
- 수혈 요법
- 약물 요법
- 골수 이식
용도별 부문
- 소아
- 성인
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Sickle Cell Anemia Therapeutics was estimated to be worth US$ 4067 million in 2024 and is forecast to a readjusted size of US$ 9988 million by 2031 with a CAGR of 13.7% during the forecast period 2025-2031.
Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird's Zynteglo and CRISPR/Vertex's Casgevy, marking a shift toward durable, potentially one-time interventions. Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.
This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Sickle Cell Anemia Therapeutics by region & country, by Type, and by Application.
The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.
Market Segmentation
By Company
- Emmaus Medical
- Theravia
- Pfizer
- Novartis
- Bluebird Bio
- Novo Nordisk
- Gamida Cell
- CRISPR Therapeutics
- GlycoMimetics
- Prolong Pharmaceuticals
- Modus Therapeutics
- Sangamo Biosciences
- Bioverativ
- Imara
- Ironwood Pharmaceuticals
Segment by Type
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
Segment by Application
- Child
- Adult
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Sickle Cell Anemia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Sickle Cell Anemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Sickle Cell Anemia Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Sickle Cell Anemia Therapeutics Product Introduction
- 1.2 Global Sickle Cell Anemia Therapeutics Market Size Forecast (2020-2031)
- 1.3 Sickle Cell Anemia Therapeutics Market Trends & Drivers
- 1.3.1 Sickle Cell Anemia Therapeutics Industry Trends
- 1.3.2 Sickle Cell Anemia Therapeutics Market Drivers & Opportunity
- 1.3.3 Sickle Cell Anemia Therapeutics Market Challenges
- 1.3.4 Sickle Cell Anemia Therapeutics Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Sickle Cell Anemia Therapeutics Players Revenue Ranking (2024)
- 2.2 Global Sickle Cell Anemia Therapeutics Revenue by Company (2020-2025)
- 2.3 Key Companies Sickle Cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Sickle Cell Anemia Therapeutics Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Sickle Cell Anemia Therapeutics
- 2.6 Sickle Cell Anemia Therapeutics Market Competitive Analysis
- 2.6.1 Sickle Cell Anemia Therapeutics Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Sickle Cell Anemia Therapeutics Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Blood Transfusion
- 3.1.2 Pharmacotherapy
- 3.1.3 Bone Marrow Transplant
- 3.2 Global Sickle Cell Anemia Therapeutics Sales Value by Type
- 3.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (2020-2031)
- 3.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Child
- 4.1.2 Adult
- 4.2 Global Sickle Cell Anemia Therapeutics Sales Value by Application
- 4.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (2020-2031)
- 4.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region
- 5.1.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2020-2025)
- 5.1.3 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2026-2031)
- 5.1.4 Global Sickle Cell Anemia Therapeutics Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 5.2.2 North America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 5.3.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 5.4.2 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 5.5.2 South America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.3.2 United States Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.4.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.5.2 China Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.6.2 Japan Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.7.2 South Korea Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.8.2 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
- 6.9.2 India Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Emmaus Medical
- 7.1.1 Emmaus Medical Profile
- 7.1.2 Emmaus Medical Main Business
- 7.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.1.5 Emmaus Medical Recent Developments
- 7.2 Theravia
- 7.2.1 Theravia Profile
- 7.2.2 Theravia Main Business
- 7.2.3 Theravia Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.2.4 Theravia Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.2.5 Theravia Recent Developments
- 7.3 Pfizer
- 7.3.1 Pfizer Profile
- 7.3.2 Pfizer Main Business
- 7.3.3 Pfizer Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.3.4 Pfizer Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.3.5 Pfizer Recent Developments
- 7.4 Novartis
- 7.4.1 Novartis Profile
- 7.4.2 Novartis Main Business
- 7.4.3 Novartis Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.4.4 Novartis Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.4.5 Novartis Recent Developments
- 7.5 Bluebird Bio
- 7.5.1 Bluebird Bio Profile
- 7.5.2 Bluebird Bio Main Business
- 7.5.3 Bluebird Bio Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.5.4 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.5.5 Bluebird Bio Recent Developments
- 7.6 Novo Nordisk
- 7.6.1 Novo Nordisk Profile
- 7.6.2 Novo Nordisk Main Business
- 7.6.3 Novo Nordisk Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.6.4 Novo Nordisk Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.6.5 Novo Nordisk Recent Developments
- 7.7 Gamida Cell
- 7.7.1 Gamida Cell Profile
- 7.7.2 Gamida Cell Main Business
- 7.7.3 Gamida Cell Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.7.4 Gamida Cell Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.7.5 Gamida Cell Recent Developments
- 7.8 CRISPR Therapeutics
- 7.8.1 CRISPR Therapeutics Profile
- 7.8.2 CRISPR Therapeutics Main Business
- 7.8.3 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.8.4 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.8.5 CRISPR Therapeutics Recent Developments
- 7.9 GlycoMimetics
- 7.9.1 GlycoMimetics Profile
- 7.9.2 GlycoMimetics Main Business
- 7.9.3 GlycoMimetics Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.9.4 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.9.5 GlycoMimetics Recent Developments
- 7.10 Prolong Pharmaceuticals
- 7.10.1 Prolong Pharmaceuticals Profile
- 7.10.2 Prolong Pharmaceuticals Main Business
- 7.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.10.5 Prolong Pharmaceuticals Recent Developments
- 7.11 Modus Therapeutics
- 7.11.1 Modus Therapeutics Profile
- 7.11.2 Modus Therapeutics Main Business
- 7.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.11.5 Modus Therapeutics Recent Developments
- 7.12 Sangamo Biosciences
- 7.12.1 Sangamo Biosciences Profile
- 7.12.2 Sangamo Biosciences Main Business
- 7.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.12.5 Sangamo Biosciences Recent Developments
- 7.13 Bioverativ
- 7.13.1 Bioverativ Profile
- 7.13.2 Bioverativ Main Business
- 7.13.3 Bioverativ Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.13.4 Bioverativ Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.13.5 Bioverativ Recent Developments
- 7.14 Imara
- 7.14.1 Imara Profile
- 7.14.2 Imara Main Business
- 7.14.3 Imara Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.14.4 Imara Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.14.5 Imara Recent Developments
- 7.15 Ironwood Pharmaceuticals
- 7.15.1 Ironwood Pharmaceuticals Profile
- 7.15.2 Ironwood Pharmaceuticals Main Business
- 7.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
- 7.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.15.5 Ironwood Pharmaceuticals Recent Developments
8 Industry Chain Analysis
- 8.1 Sickle Cell Anemia Therapeutics Industrial Chain
- 8.2 Sickle Cell Anemia Therapeutics Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Sickle Cell Anemia Therapeutics Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Sickle Cell Anemia Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
